Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Irene Becklund sold 7,573 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $30.25, for a total transaction of $229,083.25. Following the completion of the sale, the insider directly owned 11,280 shares of the company’s stock, valued at $341,220. The trade was a 40.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Irene Becklund also recently made the following trade(s):
- On Wednesday, June 17th, Irene Becklund sold 4,490 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.50, for a total value of $141,435.00.
Hims & Hers Health Stock Performance
Shares of HIMS stock opened at $31.97 on Thursday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The company’s 50 day moving average price is $26.11 and its two-hundred day moving average price is $26.61. The company has a market capitalization of $7.40 billion, a P/E ratio of -355.22, a price-to-earnings-growth ratio of 59.04 and a beta of 2.37.
Key Headlines Impacting Hims & Hers Health
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: Barclays and other commentators see breakout potential after the Novo Nordisk partnership, citing faster revenue and EBITDA growth in the second half of 2026, helped by weight-loss offerings. HIMS Stock Gained Nearly 6% On Wednesday — Barclays Sees Breakout Potential After Novo Partnership
- Positive Sentiment: Investors are also betting on Hims & Hers benefiting from the peptide market and upcoming FDA review, which could open another growth catalyst for the business. HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
- Positive Sentiment: Longer-term bullish coverage argues the Novo deal and international expansion support a path toward management’s 2030 targets of $6.5 billion+ in revenue and $1.3 billion+ in adjusted EBITDA. Hims & Hers: The Bull Case Remains Strong
- Neutral Sentiment: The stock has also been supported by discussion that short interest remains elevated, which could leave shares vulnerable to additional short-covering if momentum continues. Hims & Hers Enters A New Phase
- Negative Sentiment: Recent insider sales by executives, including COO Michael Chi and insider Irene Becklund, may create some caution, though the filings say the trades were tied to 10b5-1 plans and tax withholding from equity vesting. SEC filing for Michael Chi sale
- Negative Sentiment: Despite the upbeat narrative, prior quarterly results were weak, with only 4% revenue growth, declining margins, and a net loss, reminding investors that execution still needs to improve. Hims & Hers: The Bull Case Remains Strong
Institutional Investors Weigh In On Hims & Hers Health
A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares in the last quarter. Capital World Investors increased its stake in Hims & Hers Health by 1.2% in the third quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after acquiring an additional 223,892 shares during the last quarter. Farallon Capital Management LLC raised its position in Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. State Street Corp raised its position in Hims & Hers Health by 1.8% during the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after purchasing an additional 132,311 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Hims & Hers Health by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after purchasing an additional 608,950 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have recently issued reports on HIMS. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Citigroup increased their price target on Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. Truist Financial raised their price target on Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a report on Friday, May 22nd. Zacks Research cut shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday, June 8th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 5th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $29.37.
View Our Latest Stock Report on HIMS
Hims & Hers Health Company Profile
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Articles
- Five stocks we like better than Hims & Hers Health
- After an Initial Panic, Wall Street’s Leaning Into Apple’s New Siri AI
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
